June 11, 2008, IV meeting of the Moscow regional branch of the Russian Association of Oncological Urology “Prostate cancer treatment” took place in the Russian Scientific Center of Radiology and Nuclear Medicine in Moscow. “Pharm-Sintez” company sponsored this event. Report “Combined radiotherapy in prostate cancer treatment” was read at the meeting. It showed that neoajuvant therapy by a-GnRH, in particular by Buserelinum-depo, manufactured by AO “Pharm-Sintez”, is necessary in radiotherapy of patients with hormone-sensitive prostate cancer..